Salvador Martín‐Algarra

Author

Also Known As

A Dueñas Laita, E Calvo, F. Barron, M Torres Tortosa, Maria Gonzalez-Cao, Rafael Rosell, S Algarra, S M Algarra, S Martin Algarra, S Martin-Algarra

311

Publications

11.6K

Citations

H-Index

Concepts

All Affiliations

Clinica Universidad de Navarra Universidad de Navarra Hospital Universitario La Paz Hospital General Universitario De Valencia Hospital General Universitario Gregorio Marañón

About

Salvador Martín‐Algarra is an author at Clinica Universidad de Navarra specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	43	7.8K
2	Health Sciences	9	9	438
3	Public Health	2	2	26
4	Biostatistics	1	1	15
5	Blood Transplantation	1	1	122

Salvador Martín‐Algarra

Publications

10.9K

Citations

H-Index

Page 1

	Year	Citations
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Axel Hauschild, Jean‐Jacques Grob, Lev Demidov, The Lancet OncologyBraf-mutated Metastatic MelanomaMelanomaPathologyImmune Checkpoint Inhibitor	2012	2.9K
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab Nadeem Riaz, Jonathan J. Havel, Vladimir Makarov, Cell Microenvironment EvolutionTumor ImmunologyCancer ImmunosurveillanceImmunologyImmune Checkpoint Inhibitor	2017	2.5K
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients Miguel F. Sanmamed, José Luis Perez‐Gracia, Kurt A. Schalper, Annals of Oncology Cancer ImmunosurveillanceAnti-pd-1 TreatmentMedicineMelanomaImmunology	2017	442
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma Amod A. Sarnaik, Omid Hamid, Nikhil I. Khushalani, Journal of Clinical Oncology	2021	373
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma Catherine S. Grasso, Jennifer Tsoi, Mykola Onyshchenko, Cancer Cell Tumor ImmunologyCancer ImmunosurveillanceMelanomaImmunologyTumor Immunity	2020	361
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients Niki Karachaliou, María González‐Cao, Guillermo Crespo, Therapeutic Advances in Medical Oncology	2018	266
Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins Miguel F. Sanmamed, Omar Carranza-Rua, Carlos Alfaro, Clinical Cancer Research	2014	253
Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors Miguel F. Sanmamed, Sara Fernández-Landázuri, Carmen Rodríguez, Clinical Chemistry	2014	236
Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402) Josep M. Piulats, Enrique Espinosa, Luis de la Cruz‐Merino, Journal of Clinical Oncology	2021	224
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours Silvestre Vicent, José M. López-Picazo, Gemma Toledo, British Journal of Cancer	2004	185

Page 1